TNFα signalling predicts poor prognosis of patients with endometrial cancer. (6th April 2020)

• Record Type: Journal Article
• Authors: Wieser, Verena; Abdel Azim, Samira; Sprung, Susanne; Knoll, Katharina; Kögl, Johanna; Hackl, Hubert; Marth, Christian; Zeimet, Alain G; Fiegl, Heidelinde
• Is Part Of: Carcinogenesis. Volume 41:Number 8(2020)
• Page Start: 1065
• Page End: 1073
• Publication Date: 2020-04-06
• Subjects: Carcinogenesis -- Periodicals; Cancer -- Genetic aspects -- Periodicals; Cancer -- Prevention -- Periodicals; Cancer -- Periodicals; 616.994071
• DOI: 10.1093/carcin/bgaa034
• Languages: English
• ISSNs: 0143-3334

Abstract

Abstract: Endometrial cancer (EC) is the most common gynaecologic tumour in the Western world. Previous studies have implicated an imbalance of oestrogens and progestogens in the development of most ECs, while the role of low-grade tissue inflammation remains largely unexplored. We investigated the impact of tumour necrosis factor alpha (TNFα), a central mediator of inflammation and spermatogenesis-associated protein 2 (SPATA2), a regulator of TNF receptor signalling, on clinical outcomes in EC. We evaluated TNFA and SPATA2 transcript levels in 239 EC patients and 25 non-malignant control tissues. Findings were validated in a cohort of 332 EC patients from The Cancer Genome Atlas (TCGA). Expression of TNFA and SPATA2 was increased in EC when compared with control tissues ( P < 0.001). TNFA expression correlated with SPATA2 expression in non-malignant ( P = 0.003, r S = 0.568) and EC tissue ( P = 0.005, r S = 0.179). High TNFA and SPATA2 expression were associated with poor recurrence-free survival (RFS; P = 0.049 and P = 0.018) and disease-specific ( P = 0.034 and P = 0.002) survival. Increased SPATA2 expression was also associated with decreased overall survival (OS; P = 0.013). In multivariate analysis, both TNFA and SPATA2 were predictors of clinical outcome. The impact of SPATA2 on RFS and OS could be validated in the TCGA cohort. Our study demonstrates that ECs exhibit a TNF signature which predicts clinical outcome. These findings indicate that TNF signalling modulates the course of EC, which could be therapeutically utilized in the future. Abstract : TNFα and the TNF receptor modulator SPATA2 are highly expressed in EC, indicating engagement of TNF signalling, which serves as predictor of poor clinical outcome.